New And Emerging Rheumatic Diseases An Issue Of Rheumatic Disease Clinics Of North America E Book

In this issue of Rheumatic Disease Clinics, guest editor Dr. Erin Janssen brings her considerable expertise to the topic of New and Emerging Rheumatic Diseases. Top experts in the field cover issues such as approach to diagnosing in-born errors of immunity; Type I interferonopathies; SOCS1 and immune dysregulation; manifestations of DADA2; COPA syndrome; and more. Contains 15 relevant, practice-oriented topics including T cell tolerance/Treg defects; gene defects in early onset IBD/colitis; autoimmunity with cytoskeletal d/o - WAS, DOCK8; autoimmune and autoinflammatory neurologic conditions; genes in HLH and that predispose to MAS; mutations in severe COVID/MISC; and more. Provides in-depth clinical reviews on new and emerging rheumatic diseases, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Rheumatic Disease Clinics, guest edited by Dr. John Davis, will discuss Cancer and Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: rheumatic drugs and malignancy potential, biologic drugs and cancer, methotrexate and cancer, managing rheumatoid arthritis with cancer, Sjogren’s Syndrome and cancer, lupus and cancer, scleroderma and cancer, cancer and spondylarthritis, and cancer immunotherapy.

Guest edited by Drs. Jeffrey Curtis, Kevin Winthrop and Kaleb Michaud, this issue of Rheumatic Disease Clinics will cover several key areas of interest related to Technology and Big Data in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles in this issue include, but are not limited to: Adherence & Adverse Event Ascertainment through mHealth; Digital Patient Education and Decision Aids; Imaging in the mobile domain; Quality Measures made easier with mHealth data; Patient self-management and tracking; Motivational Counseling and SMS Reminders; Digital Interventions to build community support; Telehealth to solve cases in under-resourced areas; Trials, eConsents, Data Linkage & the Future; Clinical experience with devices; and PROMIS vs legacy data instruments.

In this first-of-its-kind issue of Rheumatic Disease Clinics, guest editor Dr. Bryant R. England brings his considerable expertise to the topic of Environmental Triggers for Rheumatic Diseases. In practical, state-of-the-art articles, top experts examine the connection between some of the most commonly seen rheumatic disease and environmental triggers for the disease. Contains 13 practice-oriented topics including inhalant and mucosal-related environmental risks for rheumatoid arthritis; lifestyle, hormonal, and microbial-related environmental risks for rheumatoid arthritis; environmental risks for systemic lupus erythematosus; environmental risks for osteoarthritis; targeting environmental risks to prevent rheumatic diseases; and more. Provides in-depth clinical reviews on environmental triggers for rheumatic diseases, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Rheumatic Disease Clinics, guest edited by Dr. Alfred Kim and Zahi Touma, will discuss a number of key topics surrounding Lupus. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: Interferons in SLE, NETosis and neutrophils in SLE, AMP update in lupus nephritis, Patient-reported outcomes, Complement, T cells in SLE, B cells in SLE, Outcome measures for SLE clinical trials, Mitochondrial physiology in SLE, Pregnancy, Lupus cohorts, Innovative trials and new opportunities in SLE, Classification and diagnosis of SLE, and Updates on SLE Treatment.

In this issue of Rheumatic Disease Clinics, guest editor Dr. Erin Janssen brings her considerable expertise to the topic of New and Emerging Rheumatic Diseases. Top experts in the field cover issues such as approach to diagnosing in-born errors of immunity; Type I interferonopathies; SOCS1 and immune dysregulation; manifestations of DADA2; COPA syndrome; and more. Contains 15 relevant, practice-oriented topics including T cell tolerance/Treg defects; gene defects in early onset IBD/colitis; autoimmunity with cytoskeletal d/o - WAS, DOCK8; autoimmune and autoinflammatory neurologic conditions; genes in HLH and that predispose to MAS; mutations in severe COVID/MISC; and more. Provides in-depth clinical reviews on new and emerging rheumatic diseases, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Rheumatic Disease Clinics, edited by Drs. John Imboden and Sarah Goglin, will cover a variety of important aspects of the neurological manifestations of rheumatic diseases. Topics discussed in the issue will include: Primary vasculitis of the central nervous system; Neurologic manifestations of primary Sjogren Syndrome; Neurologic manifestations of antiphospholipid antibody syndrome; Neurologic manifestations of rheumatoid arthritis and ankylosing spondylitis; Neuromyelitis optica; Neurosarcoid; Central nervous system infections associated with immunosuppressive therapy; and Neurologic manifestations of IgG4-related disease, among others.

Guest edited by Jonathan Kay, this issue of Rheumatic Disease Clinics will cover the latest research and evidence surrounding the diagnosis, treatment and management of rarely seen rheumatic diseases.